Tuberculosis and poverty: the contribution of patient costs in sub-Saharan Africa – a systematic review by Barter, Devra M et al.
 
Tuberculosis and poverty: the contribution of patient costs in sub-
Saharan Africa – a systematic review
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Barter, Devra M, Stephen O Agboola, Megan B Murray, and Till
Bärnighausen. 2012. Tuberculosis and poverty: the contribution
of patient costs in sub-Saharan Africa – a systematic review.
BMC Public Health 12:980.
Published Version doi:10.1186/1471-2458-12-980
Accessed February 19, 2015 11:58:08 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11029505
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAARESEARCH ARTICLE Open Access
Tuberculosis and poverty: the contribution
of patient costs in sub-Saharan Africa – a
systematic review
Devra M Barter
1*, Stephen O Agboola
1, Megan B Murray
2 and Till Bärnighausen
1,3
Abstract
Background: Tuberculosis (TB) is known to disproportionately affect the most economically disadvantaged strata of
society. Many studies have assessed the association between poverty and TB, but only a few have assessed the
direct financial burden TB treatment and care can place on households. Patient costs can be particularly
burdensome for TB-affected households in sub-Saharan Africa where poverty levels are high; these costs include
the direct costs of medical and non-medical expenditures and the indirect costs of time utilizing healthcare or lost
wages. In order to comprehensively assess the existing evidence on the costs that TB patients incur, we undertook
a systematic review of the literature.
Methods: PubMed, EMBASE, Science Citation Index, Social Science Citation Index, EconLit, Dissertation Abstracts,
CINAHL, and Sociological Abstracts databases were searched, and 5,114 articles were identified. Articles were
included in the final review if they contained a quantitative measure of direct or indirect patient costs for treatment
or care for pulmonary TB in sub-Saharan Africa and were published from January 1, 1994 to Dec 31, 2010. Cost data
were extracted from each study and converted to 2010 international dollars (I$).
Results: Thirty articles met all of the inclusion criteria. Twenty-one studies reported both direct and indirect costs;
eight studies reported only direct costs; and one study reported only indirect costs. Depending on type of costs,
costs varied from less than I$1 to almost I$600 or from a small fraction of mean monthly income for average
annual income earners to over 10 times average annual income for income earners in the income-poorest 20% of
the population. Out of the eleven types of TB patient costs identified in this review, the costs for hospitalization,
medication, transportation, and care in the private sector were largest.
Conclusion: TB patients and households in sub-Saharan Africa often incurred high costs when utilizing TB treatment
and care, both within and outside of Directly Observed Therapy Short-course (DOTS) programs. For many households,
TB treatment and care-related costs were considered to be catastrophic because the patient costs incurred commonly
amounted to 10% or more of per capita incomes in the countries where the primary studies included in this review
were conducted. Our results suggest that policies to decrease direct and indirect TB patient costs are urgently needed to
prevent poverty due to TB treatment and care for those affected by the disease.
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In 2009, tuberculosis (TB) was the world’s 7th leading
cause of death, resulting in 1.7 million deaths worldwide,
more than 9.4 million new infections and 14 million
prevalent cases [1]. TB is often known as “a disease of
the poor” because the burden of TB follows a strong
socioeconomic gradient both between and within coun-
tries, and also within the poorest communities of coun-
tries with high TB incidence [2]. Some studies have
shown a strong association between poverty and TB and
have demonstrated that poor and vulnerable groups are
at an increased risk of TB infection, have a higher preva-
lence of disease, have worse outcomes (including mortal-
ity), and display worse TB care-seeking behaviors [3-8].
Risk factors for these TB-related outcomes include struc-
tures, behaviors and other diseases commonly associated
with poverty - overcrowded living or working conditions,
poor nutrition, smoking, alcoholism, diabetes, exposure
to indoor air pollution and HIV [2,7-10].
It is also well-known that TB can contribute to poverty
by reducing patients’ physical strength and ability to
work [8,11-13]. However, another pathway through
which TB can affect households’ economic situation, the
costs patients incur when utilizing TB care, has been less
studied. These costs include both direct out-of-pocket
costs incurred when seeking treatment and care and the
indirect, or time costs, associated with utilizing health-
care. While most countries with high TB burden pro-
vide free sputum smear microscopy for patients
with suspected pulmonary TB, more than half of these
22 countries charge for other TB-related diagnostic
tests such as radiography, sputum culture, and drug-
susceptibility testing [14]. Under Directly Observed
Therapy Short-course (DOTS) programs, all high burden
TB countries provide free first line anti-TB medication,
but many patients purchase anti-TB drugs in private
pharmacies (some without prescriptions), which can be
costly [14,15]. In high TB burden countries, 60% of over-
all health expenditure is in the private sector, and a large
proportion of these expenditures are paid out-of-pocket
by patients [14].
A number of previous studies have documented the
downstream consequences of the direct and indirect
costs that TB patients incur. More than 50% of TB
patients have been reported to experience financial diffi-
culties due to TB [16], and these costs can be “cata-
strophic” in that they amount to more than 10%
of patients’ or households’ annual income [17-19]. TB
patient costs have been shown to lead to reduced food
consumption, diversion of resources from other types of
healthcare, taking children out of school, and borrowing
or selling assets [17,19-21]. Furthermore, financial con-
straints have been shown to predict non-adherence to
TB medication [16]. In general, the World Health
Organization (WHO) estimates that 100 million people
every year fall into poverty from paying for health services
[22].
One earlier review reports on the overall costs TB-
patients in Africa face during the pre- and post-
diagnosis phases of TB treatment and care as well as
coping mechanisms for catastrophic costs [23]. In this
study, we expand on this previous assessment by broad-
ening the evidence base on TB patient costs in sub-
Saharan Africa through screening of additional databases
and broadening the study design inclusion criteria,
systematically identifying the particular types of TB
patient costs (both direct and indirect), systematically
reviewing the evidence on the cost quantities for each
cost type, and providing benchmarks for the magnitude
of cost burdens on TB patients and households.
Methods
Data sources and search strategies
We used eight electronic databases to identify papers
reporting on patient costs for TB care in sub-Saharan
Africa available by January 3-4, 2011: PubMed, Embase,
Science Citation Index, Social Science Citation Index,
EconLit, Dissertation Abstracts, Cumulative Index to
Nursing and Allied Health Literature (CINAHL), and
Sociological Abstracts. Each search strategy comprised a
Boolean operator of “and” with two elements: tuberculosis
and cost/economic aspects. For the PubMed search,
MeSH and “all fields” terms comprising tuberculosis and
OR fields for cost estimates such as “employment,”“ out of
pocket,”“ patient costs” and MeSH terms for “costs and
cost analysis” were used. Similar search strategies were
employed for the other 7 databases (see Additional file 1
for the precise search algorithms for each database). Each
database was searched from the earliest referenced publi-
cation date through January 1, 2011. Studies were
included regardless of language. Two reviewers independ-
ently screened articles identified from the initial search of
the databases by title and/or abstract.
To identify additional articles, conference abstracts
written in English from 1994-2010 from the Inter-
national Union Against Tuberculosis and Lung Disease
(IUATLD) annual conference were searched. Further-
more, we performed a secondary search of reference lists
of articles identified through the database search, includ-
ing both the primary studies included in our synthesis
and review studies.
Articles were considered for inclusion if they con-
tained a quantitative measure of a direct or indirect
patient-incurred cost (including time costs) relating to
TB treatment or care for adult pulmonary tuberculosis.
Following Rajeswari et al. [24] and Jackson et al. [25]
we defined costs as follows: Direct costs included both
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costs of medication or diagnostic tests) and non-medical
expenditures (such as money spent on travel, lodging,
and food for both patients and caregivers). Indirect costs
were defined as time costs associated with utilizing
healthcare, or time costs converted into monetary units
based on loss of wages for both patients and caregivers
or decreased earning ability [26].
We excluded the following articles: i) published before
1994 when DOTS was officially launched as a frame-
work for a TB control strategy recommended by the
WHO [27]; ii) not taking place in Sub-Saharan Africa;
iii) not pertaining to TB; iv) not involving human
subjects; v) on MDR-TB, HIV/TB co-infection, latent
or pediatric TB; vi) focusing solely on diagnostic tests,
screening tests, or vaccinations; vii ) not containing any
primary data on cost estimates or economic analysis; or
viii) not relating to individual patient costs.
Articles were assessed for study quality. In particular,
we examined the studies to ensure that we included only
those in our final review that had clearly defined objec-
tives, clearly defined study populations, and a quan-
titative measure of patient-costs. Additionally, articles
were categorized by study type and whether costs were
incurred pre- or post-diagnosis. We adhered to the
PRISMA guidelines [28].
Data extraction and analysis
In addition to study-specific variables (authors, study
type, year, location, setting, period of observation, pop-
ulation under study, and study objectives), the two
reviewers extracted patient-borne quantitative direct and
indirect cost measurements. We extracted only costs
measured empirically in the reviewed studies. Costs that
were extrapolated or projected in mathematical models
were not included in the analysis. Data were categorized
into costs related to health insurance, prepayment,
consultation or provider fees, hospitalization, medica-
tion, and diagnostic test costs, traditional healer and
food costs, travel costs, time costs, reported impact on
income, reported direct, indirect, and total costs, care-
giver costs and catastrophic costs.
To compare costs expressed in different currencies
and measured in different years, we converted all cost
180 estimates into 2010 international dollars (I$). We
rounded all cost estimates to the nearest integer except
for costs less than 1I$, which we rounded to the second
decimal place. For costs that were presented in US$,
costs were first converted to respective local currency
units using OANDA currency conversions [29] based on
exchange rates at the commencement of the study
period. For studies that did not specify the year or
period of currency estimates, January 1
st of the beginning
of the study year was used as a standard conversion date
except for one study in Botswana [30], for which conver-
sion rates were only available beginning November 1, 1993
instead of January 1, 1993, and for one study in Uganda
[31], for which conversion rates were available beginning
January 1, 1996 instead of January 1, 1992. Next, local cur-
rency units were adjusted to 2010 rates using the Inter-
national Monetary Fund’s database on average consumer
price inflation over time [32]. Finally, costs were adjusted
to 2010 international dollars based on the World Bank’s
purchasing power parity (PPP) conversion factors (in local
currency units per international dollar) [33].
To compare costs across studies, we report travel costs
as single visit costs and hospitalization costs over the entire
treatment period. To provide a benchmark for the magni-
tude of cost burdens of TB care on patients, we expressed
the expenditures as percentage of per-capita annual (or
monthly) GDP (in I$) of the country and in the year when
the study, which generated the cost estimates, was con-
ducted. The per-capita GDP figures are taken from the
World Development Indicators published by the World
Bank [33]. Per-capita GDP, i.e., the average income, is one
benchmark that is meaningful to understand and com-
monly used for such purposes, and we thus use it here.
However, since TB is a disease that predominantly affects
poorer populations, we also express the cost estimates as a
percentage of an alternative income benchmark—the per-
capita income of the income-poorest 20% of the popula-
tion, calculated according to the following equation:
We chose these two income benchmarks, rather than
study population-specific incomes, because very few of
the studies included in our review reported the study
population income. We also report whether the pa-
tient costs of TB treatment are “catastrophic” for the
person of average income or the person of average
income amongst the income-poorest 20% of the
population, classifying costs as “catastrophic” when
they were at least 10% of average annual income for
t h er e s p e c t i v ep o p u l a t i o n .While definitions of cata-
strophic expenditures commonly relate to household
income, [18,34-37] we chose to use 10% of annual
individual income as a benchmark for catastrophic
costs because for most studies we lack household-
level income data as well as the household-level TB
data that would be necessary to judge whether the
financial burdens of TB care and treatment is “cata-
strophic” or not. Without the latter data, household-
level income data is not an appropriate indicator
since TB tends to cluster in households [38-40].
Total GDP  Income share of the incomepoorest 20% of the population
Total population size  0:2
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5,114 articles were identified from the initial search of the
eight databases. After excluding 1,112 duplicate articles,
1,510 were excluded because they did not include TB as a
major subject heading, 777 did not include cost estimates,
632 were published before 1994, 427 focused solely on
diagnostic tests, screening tests or vaccinations, 331 did
not include patient cost estimates, and 95 did not involve
human subjects. Reviewing the full text of the remaining
230 articles, we found that 55 did not include a quantita-
tive cost measurement; 14 were reviews, commentaries,
letters or editorials that did not include primary data; 7
were on pediatric TB, 13 on MDR-TB, 6 on latent TB, 4
on HIV/TB, 105 studies did not take place in sub-Saharan
Africa; and 2 studies were by the same authors and
included the same data (leading to the exclusion of 1 of
the 2 studies). This selection process resulted in 25 rele-
vant studies; 5 additional relevant publications were iden-
tified through the search of the conference database and
reference lists, so that a total of 30 articles were included
in the final synthesis of our review (see Figure 1).
Table 1 describes each of the 30 studies in terms of
their study populations, main objectives, types of cost
estimates, and time period in which costs were incurred
(pre- vs. post-diagnosis). Eight studies reported direct
costs, one study reported indirect costs, and twenty-one
studies reported both indirect and direct costs. Table 2
describes the cost categories, including definitions for
each cost type, whether the costs are considered direct
or indirect, whether the cost are incurred pre- or post-
diagnosis, the number of studies reporting a particular
cost type, and the cost range and median among all
studies reporting the cost type.
Health insurance, prepayment fees, consultation
and private provider fees
Two studies reported health insurance fees that ranged
from I$2 to I$3 in Zambia [41,59], and four studies
reported consultation or prepayment fees that ranged
from I$2 in Ethiopia [55] and Botswana [30] to I$7 in
Zambia [58]. Patients who did not seek care from the
public sector paid fees for care in the private sector.
Four studies noted such fees for private services, which
ranged from I$24 (median I$10) in Zambia [58] to I$141
in Uganda [47] (see Table 3). Additionally, one study
from Uganda reported the practice of “tipping” health-
care providers in the range of I$5- I$40 [46].
Hospitalization, medication, and diagnostic tests costs
Ten studies reported hospitalization expenses. Costs
ranged from I$4 in Uganda [61] to over I$530 in Kenya
[60]. Some patients were required to pay hospital admis-
sion fees. Patients in Freetown, Sierra Leone paid an
average of I$1 at a missionary hospital and I$47 at a
government hospital, which included the cost of food
[52]. Five studies reported medication costs that ranged
from I$20 in Uganda [46] to I$548 in Nigeria [42] (see
Table 4). Moreover, one study from Kenya reported that
patients paid I$46 monthly for syringes and needles
for streptomycin treatment (not including streptomycin
itself) [43]. Three studies reported diagnostic test costs
other than sputum smears which ranged from I$7 for
chest radiographs [41] to I$10 for examination, labora-
tory, and X-ray fees in Tanzania [68].
Traditional healer and food costs
Five studies reported that patients paid between I$3 in
Malawi [44] to I$563 in Uganda [47] to see traditional
healers, and four studies reported the cost of food,
which ranged from I$4 (interquartile range (IQR) I$1-
I$7) in Zambia to I$36 in Ethiopia and Zambia (median
I$19) for “special food” [41,48,58] (see Table 5).
Travel costs
Eighteen studies reported travel costs for patients, fam-
ilies, or guardians for single visits or for multiple visits
during treatment. Costs ranged from less than I$1 in
South Africa for a single health clinic visit [51,63] to
I$70 in Ethiopia for pretreatment transportation costs
[65] (see Table 6). Travel time also varied from 48 min-
utes in Cape Town, South Africa [63] and Kampala,
Uganda [46] to almost 70 hours in Ethiopia under a
health-facility based DOTS system for a single visit [48].
One study from Zambia distinguished between pre and
post diagnosis travel costs: pre-diagnosis travel costs were
I$3 (IQR I$1- I$7) while post-diagnosis costs were I$11
(IQR I$4- I$29) [41]. In addition to travel costs, one study
reported accommodation costs (in Ethiopia) [55].
Time costs
Twenty-one studies reported time costs. Clinic visit wait
time varied from 30 minutes in Limpopo Province,
South Africa [49] to 111 minutes in Kampala, Uganda
[46]. One study from Uganda reported that patients
spent on average 22 minutes for a volunteer-supervised
outpatient DOTS visit or I$0.23 (95% CI I$0.00- I$0.42)
in lost income, and an average of 110 minutes for a
health-facility visit, or I$1 (95% CI I$1- I$2) in lost in-
come [61].
Lost work time varied by treatment system. For hospi-
talized patients in South Africa, each hospital day led to
an average of 402 minutes of lost work time (I$7 in lost
income) compared to 128 minutes (I$2) for a health
clinic visit, 50 minutes (I$0.85) for a DOTS visit with a
community health worker chosen as a treatment super-
visor, and 4 minutes (I$0.51) with another type of health
worker chosen as a supervisor [51]. In Malawi patients
lost an average of 22 workdays resulting in an average
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that patients missed an average of 18 workdays before
being diagnosed with TB [58] and 48 days of missed work
in total [59]. Foregone earnings reported for any type of
care-seeking activity ranged from I$3 in South Africa [63]
to I$169 in Tanzania [68].
Reported impact on income
Five studies surveyed patients on their salaries and
reported the impact of TB patient costs on household
incomes [41,55,58,59,65]; one study used average house-
hold income estimates from an external source to calcu-
late the impact of TB patient costs on household incomes
[54]. In Malawi, patients spent between 129% and 244% of
their mean monthly income (MMI) on TB diagnosis [54].
In Zambia, patients spent 16% of their MMI on transpor-
tation costs and 66% of their MMI on food [59]. Direct
medical expenditures ranged from between 10% of MMI
for men and 132% of MMI for women in Zambia [41] to
31% for all patients in Ethiopia [55], while non-medical
expenditures ranged from 42% in Ethiopia [55] to 55% of
MMI in Zambia [58]. In Ethiopia, 48% and 35% of annual
household income was lost due to TB treatment and
pretreatment costs, respectively [65].
Reported direct, indirect and total costs
Eight studies reported aggregated overall direct costs,
and six studies reported aggregated overall indirect costs
incurred by patients (although authors defined direct
and indirect costs differently). Reported direct costs
Figure 1 Flowchart of the systematic review.
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Author (Year) Country Type of study Population under study Primary objectives Types of costs reported Time period of costs
(Pre vs. post diagnosis)
Aspler, et al. (1998) [41] Zambia Cross-sectional 103 patients aged ⩾18 years
with active or extra-pulmonary
TB who had been on
treatment for 6-10 weeks
To estimate TB patient
costs for treatment and
diagnosis and cost
determinants
Pre-diagnosis, treatment,
time, travel, medication,
consultation, hospitalization,
food, health insurance, and
diagnostic test costs
Both
Awofeso, N. (1998) [42] Nigeria Prospective cohort 2144 symptomatic
smear-positive patients
in two study periods
To discuss the implications
of pre-payment versus
free medication therapy
on treatment and case-
finding of TB patients
Medication costs Post-diagnosis
Bevan, E. (1997) [43] Kenya Unknown Unknown Letter to describe other
costs associated with DOTS
Daily inpatient care,
travel, and other
medical expenses
Post-diagnosis
Brouwer, et al. (1998) [44] Malawi Cross-sectional 89 smear-positive pulmonary
TB patients admitted to
Queen Elizabeth Central
Hospital
To investigate how TB
patients utilize traditional
healers and traditional
medicine in their care-
seeking behaviors
Total fixed and variable
costs, time, and
traditional healer costs
Pre-diagnosis
Cambanis, et al. (2005) [45] Ethiopia Cross-sectional 243 patients undergoing
sputum examination for
TB diagnosis
To assess factors related
to patient delay in
presenting to health
services for the diagnosis
of TB
Time and travel costs Pre-diagnosis
Chard, S. (2001) [46] Uganda Cross-sectional 89 female patients aged ⩾
18 years identified from
a TB clinic
To examine treatment
seeking, health beliefs,
and social networks of
female Ugandan TB patients
Time, travel, medication,
traditional healers, and
costs for “tipping”
healthcare providers
Both
Chard, S. (2009) [47] Uganda Cross-sectional 65 women aged ⩾18 years
with a diagnosis of pulmonary
TB, and receiving outpatient
TB treatment from one of
three TB clinics
To explore the TB treatment-
seeking process of Ugandan
women in order to
determine the routes to
effective government TB
treatment
Private providers and
traditional healer costs
Both
Datiko and Lindtjørn (2010) [48] Ethiopia Cost-effectiveness
analysis
229 smear-positive patients To determine the cost and
cost-effectiveness of
involving health extension
workers in TB treatment
under a community-based
model
Time, caregiver, food,
direct, and total costs
Post-diagnosis
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Edginton, et al. (2002) [49] South Africa Qualitative 114 hospital TB patients and
75 clinic TB patients and
community members were
interviewed
To assess the beliefs and
experiences about TB from
the perspective of patients
and community members
in order to assess the
impact of presentation to
health services and treatment
adherence
Time and travel costs Post-diagnosis
Floyd, et al. (2003) [50] Malawi Cost-effectiveness
analysis
2,174 new smear-positive
and -negative patients
registered for treatment in
1997; 2,821 new smear-
positive and -negative patients
registered for treatment
in 1998
To assess the cost and
cost-effectiveness of new
treatment strategies for
new pulmonary TB patients
introduced in Malawi in 1997
Time, travel,
hospitalization,
caregiver, and DOTS
costs
Post-diagnosis
Floyd, et al. (1997) [51] South Africa Cost-effectiveness
analysis
New smear-positive adult
patients
To conduct an economic
evaluation of directly
observed treatment and
conventionally delivered
treatment for the
management of new adult
TB cases
Time, travel,
hospitalization, total,
and DOTS costs
Post-diagnosis
Gibson, et al. (1998) [52] Sierra Leone Cross-sectional 54 inpatients, 18 outpatients,
and 17 staff members in 6
TB Centers
To evaluate the impact of
patient poverty and
staff salaries on patient
costs for TB treatment
within a sub-national
TB program
Pre-program, program
time, and total costs
Both
Harper, et al. (2003) [53] The Gambia Qualitative 443 patients and clinic staff
participated in focus groups,
in-depth interviews, and
semi-structured interviews
To evaluate the factors related
to shortages of case tracing
and adherence to treatment
using qualitative methods
with a cohort of TB patients
Travel and private
treatment costs
Both
Kemp, et al. (2007) [54] Malawi Cross-sectional 179 smear-positive and
-negative TB patients who
were in the intensive phase
of treatment
To assess the relative
costs of accessing a TB
diagnosis for the poor
and for women in urban
Lilongwe, Malawi, where
public health services are
accessible within 6km
and are provided free of
charge
Time, travel,
medication,
and food costs
Both
Mesfin, et al. (2010) [55] Ethiopia Prospective cohort 537 newly diagnosed
smear-positive
pulmonary TB patients
and 387 newly diagnosed
smear-negative pulmonary TB
patients ≥15
To investigate costs of
TB diagnosis incurred by
patients, their escorts,
and the public health
system in 10 districts in
Ethiopia
Caregiver, time,
travel, medication,
consultation, hospital
admission, and
lodging costs
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Moalosi, et al. (2003) [56] Botswana Cost-effectiveness
analysis
50 caregivers of TB patients
on home-based care
To determine the affordability
and cost-effectiveness of
home-based DOTS vs. hospital-
based DOTS for TB patients and
to describe the characteristics
of patients and their caregivers
Total, time, travel,
medication and
hospitalization costs
for caregivers
Both
Needham, et al. (1996) [57] Zambia Cross-sectional 23 adult inpatients and
outpatients with a diagnosis
of pulmonary TB
Letter in response to Pocock
et al. 1996 to assess patient-
related economic barriers to
TB diagnosis in Lusaka, Zambia
Medical, non-medical,
time, and caregiver
costs
Both
Needham, et al. (1998) [58] Zambia Cross-sectional 202 adult inpatients and
outpatients registering with
new pulmonary TB at the
Chest Clinic
To study the pre-diagnosis
economic impact burden and
barrers to care seeking for TB
patients in urban Zambia
Time, travel, consultation,
caregiver, private
provider, traditional healer,
insurance, diagnostic,
treatment, and food costs
Both
Needham, et al. (2004) [59] Zambia Qualitative 202 adult patients with
pulmonary tuberculosis
To assess the barriers to
successful care seeking faced
by TB patients in urban Zambia
Time, travel, caregiver,
and government health
insurance costs
Pre-diagnosis
Nganda, et al. (2003) [60] Kenya Cost-effectiveness
analysis
New smear-positive, new
smear-negative and extra-
pulmonary adult patients; for
each type of patient, two
alternative approaches to
treatment were evaluated:
the conventional approach
used until September 1997
and the new approach
introduced in October 1997
To assess the cost and cost-
effectiveness of new treatment
strategies, involving
decentralization of care from
hospitals to peripheral health
facilities and the community,
compared to the conventional
approaches used until
October 1997
Total, travel,
hospitalization,
TB clinic, and DOTS
costs
Post-diagnosis
Okello, et al. (2003) [61] Uganda Cost-effectiveness
analysis
New smear-positive pulmonary
patients under two strategies:
the conventional hospital-
based approach used from
1995 thorough 1997, and the
new community-based
approach introduced in 1998
To assess the cost and cost-
effectiveness of conventional
hospital-based care with the
new community-based care
for new smear-positive
pulmonary TB patients
Time, travel,
hospitalization, and
total DOTS costs
Post-diagnosis
Pocock, et al. (1996) [62] Malawi Cross-sectional 100 adult patients with smear-
positive and extrapulmonary
TB admitted to the TB ward,
Queen Elizabeth Central
Hospital, for 2 months of
treatment
Letter investigating impacts
of long hospitalization from
the patients’ perspective
Time costs Post-diagnosis
Saunderson, P.R. (1995) [31] Uganda Cost-effectiveness
analysis
34 patients attending a
hospital run by a non-
governmental
organization
To analyze the costs and
cost-effectiveness of the
current TB control strategy
and an alternative ambulatory
treatment strategy
Total, time, hospitalization,
and pre-diagnosis costs
Both
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Sinanovic, et al. (2003) [63] South Africa Cost-effectiveness
analysis
New smear-positive
and retreatment pulmonary
TB patients started on
treatment in two townships
of Metropolitan Cape Town
(Guguletu, where both clinic
and community care were
provided, and Nyanga, where
only clinic-based care was
provided)
To evaluate the affordability
and cost-effectiveness of
community involvement in
TB care
Total, time, and
travel costs
Post-diagnosis
Sinanovic and Kumaranay-ake
(2006) [64]
South Africa Cost-effectiveness
analysis
1,182 new sputum positive
patients at 2 public-private
workplace sites (PWP), 2 public-
non-governmental organization
partnership sites (PNP) and 2
purely public sites
To estimate the cost and cost-
effectiveness of different types of
public-private-partnerships in TB
treatment and the financing
required for the different models
from the provincial TB program from
the patient and provider perspective
Total, time, and
travel costs
Post-diagnosis
Steen and Mazonde (1999) [30] Botswana Cross-sectional 212 New and retreated
patients with smear-positive
pulmonary TB
To estimate the health-seeking
behaviors of TB patients and their
beliefs and attitudes of the disease
Outpatient fees Post-diagnosis
Vassall, et al. (2010) [65] Ethiopia Cross-sectional 250 patients ⩾ 15 years using
TB-HIV pilot services and
diagnosed with and being
treated for TB, HIV, or both
To measure patients costs of
TB-HIV services from hospital-
based pilot sites for collaborative
TB-HIV interventions
Direct, indirect,
transport, total
Both
Wandwalo, et al. (2005) [66] Tanzania Cost-effectiveness
analysis
42 treatment supervisors and
103 new smear-positive, smear-
negative, and extrapulmonary
TB patients 5 years
To determine the cost and cost-
effectiveness of community-based
DOTS versus health facility
treatment of TB in urban Tanzania
Direct, indirect, time,
and total costs
Post-diagnosis
Wilkinson, et al. (1997) [67] South Africa Cost-effectiveness
analysis
TB patients under the Hlabisa
strategy (1991-preent), the
former Hlabisa strategy (until 1991),
the Department of Health strategy,
and the SANTA strategy based on
sanatorium care
To conduct an economic analysis
of the Hlabisa community-based
DOTS management compared to
three alternative strategies
Total, hospitalization,
and travel costs
Post-diagnosis
Wyss, et al. (2001) [68] Tanzania Cross-sectional 191 TB cases in 3 surveillance
areas who had smear-positive,
extrapulmonary, or relapse TB
To assess household level costs
of TB and to compare them with
provider costs of the National TB
Control Program
Diagnostic test, time,
traditional healer, private
provider, hospitalization,
caregiver, and travel costs
Both
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0ranged from I$11 in Zambia [41] to over I$527 in Ethiopia
[65], while indirect costs ranged from I$21 in Zambia [41]
to I$145 in Ethiopia [55]. Thirteen studies reported overall
total costs (direct and indirect), which ranged from I$2 in
South Africa [63] to I$584 in Uganda [31] (see Table 7).
Five studies reported the percentage of all costs that
patients paid out-of-pocket. In South Africa, out-of-pocket
expenses varied by district in which patients were respon-
sible for paying between 13% and 34% of all costs [51].
Similarly, in Tanzania patients paid between 13% and 30%
of total costs in community-based DOTS and health
facility-based DOTS programs, respectively [66]. In Malawi
and Ethiopia, patients paid close to 50% of total costs of
their care.
Caregiver and guardian costs
Eight studies reported both direct and indirect costs in-
curred by TB patients’ guardians or caregivers. Direct
costs included transportation costs that ranged from
less than I$1 (standard deviation [SD] I$4) under a
community-based DOTS program in Ethiopia [48] to I
$27 in Botswana [56]. The amount of time spent travel-
ing for one care-related visit ranged from 20 minutes in
Botswana [56] to 17 hours (median 0) in Ethiopia [55].
Other direct costs for caregivers included food costs
that ranged from I$3 (standard deviation [SD] I$5) in
Ethiopia [48] to I$1,209 in Botswana [56] and time
spent providing care-giving activities, which ranged
from 1 hour each day in Botswana [59] to 6 days
Table 2 Types of Costs
Cost categories Definition Direct or
indirect
Pre- or
post-diagnosis
Number of
studies reporting
cost category
Range (median)
of costs
Health insurance Costs required for national health
insurance schemes to finance
TB care
Direct Pre-diagnosis 2 I$2- I$3 (I$2)
Consultation or
prepayment fees
Costs charged by providers before
diagnosis or treatment
Direct Pre-diagnosis 4 I$2- I$7 (I$3)
Private provider fees Costs charged in the private sector
rather than the public sector
Direct Both 4 I$24- I$141 (I$41)
Hospitalization Costs associated with hospitalization
due to TB
Direct Post-diagnosis 10 I$1- I$530 (I$80)
Medication Costs of medications including
standard TB treatment under
non-DOTS systems and other drugs
Direct Post-diagnosis 5 I$15- I$548 (I$21)
a
Diagnostic tests Costs for tests other than sputum
microscopy such as x-rays, chest
radiographs, or other laboratory tests
Direct Pre-diagnosis 3 I$7- I$10 (I$9)
Traditional healer Costs associated with seeking
traditional healers before Western
medical care
Direct Pre-diagnosis 5 I$4- I$563 (I$15)
Food Costs for regular food and food
separate from normal diets such as
potatoes, eggs, meat, fruit, and
soft drinks [58]
Direct Post-diagnosis 4 I$4- I$36 (I$10)
Travel Costs for travel association with
pre-diagnosis, consultation,
diagnosis, treatment, pill collection,
DOTS and follow-up treatment visits.
Direct Both 18 I$0.17- I$70 (I$5)
Time Time and indirect costs associated
with time spent seeking/receiving
care and lost work time
Indirect Both 21 I$0.23- I$412 (I$16)
b
Caregiver Costs to those accompanying
patients to TB care visits, retrieving
medications on their behalf, or cost
of care-giving activities. Direct costs
encompass travel expenses, food,
or other costs such as paying for
an overnight stay when making a
long journey. Indirect costs include
loss of income and time spent
accompanying patients or providing
care-giving activities.
Both Both 8 I$0.41- I$1,510 (I$11)
c
a Note: Some medication estimates also include the cost of user/consultation fees;
b Costs include only reported costs of income lost due to time;
c Based on
different categories of costs.
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Indirect costs included foregone earnings for caregivers
which ranged from I$19 (median $10) in Zambia [58]
to I$89 in Ethiopia [55]. Total reported caregiver cost
ranged from I$24 (median I$12) in Zambia [58] to I
$1510 under a home-based care strategy in Botswana
[56].
Catastrophic costs
Twenty studies reported costs that were found to be
catastrophic for those with average income, and twenty-
five studies had costs that were catastrophic for the lowest
income earners (see Table 8). Catastrophic costs constituted
between 11% of average annual income in The Gambia for
private providers [53] and almost three times average an-
nual income in Ethiopia for total pretreatment costs [65].
For those in the income-poorest 20% of a country’s
population, catastrophic costs constituted between 10%
of annual income for traditional healers in Tanzania
[68] to roughly ten times annual income for hospitalization
costs in Malawi [50].
Two aspects of our extracted data are important to
note in this context: First, we extracted data for a range
of different cost categories (Tables 1, 2, 3, 4, 5). For all
cost categories, there are at least a few studies reporting
catastrophic costs according to our definition both for
those with average income and those with the average
income among the income-poorest 20% of the popula-
tion: traditional healer, food, travel, private provider,
medication, “tipping” providers, hospitalization, care-
giver, and overall direct, indirect and total costs. Second,
the extracted costs are presented in the tables in the
units they were reported in the original papers because
we did not have sufficient information, either from the
papers or external sources, to allow translation into a
common unit. However, catastrophic costs were found
in all units of reported costs, including per-visit, per
time period, and per treatment course and in both the
pre- and post-diagnosis periods.
Discussion
In expanding on a previous review of TB patient costs in
sub-Saharan Africa [23], we extended the evidence base
on TB patient costs in sub-Saharan Africa through
screening of additional databases and broadening the
study design inclusion criteria. We have further added to
the literature by systematically identifying the particular
types of costs TB patient incur and by systematically
reviewing the evidence on the cost quantities for each
cost type. Our review furthermore provides benchmarks
for the magnitude of these cost burdens by comparing
them to average income earners and the average income
of the income-poorest 20% of the population.
Table 3 Health insurance, consultation/prepayment fees and private provider fees
Author(s) (year) Country Cost
estimate (I$)
% Annual per-
capita income
(entire population)
% Annual per-
capita income
(income-poorest 20%
of the population)
Notes
Health insurance costs
Aspler, et al. [41] Zambia 2 0.43 2 67% of patients reported paying
median health insurance user fees
(IQR I$1.79- I$1.97)
Needham, et al. [59] Zambia 3 0.69 3
a Mean monthly fees for government-
sponsored health insurance
(range I$2-I$3)
Consultation/prepayment fees
Aspler, et al. [41] Zambia 4 0.78 4 Median one time consultation fee
(IQR I$4- I$7)
Mesfin, et al. [55] Ethiopia 2 0.93 2 Mean consultation fees per visit
(median I$0)
Needham, et al. [58] Zambia 7 2 10 Mean one-time consultation fees
(median I$8)
Steen and Masonde [30] Botswana 2 0.06 0.43
b One-time prepayment outpatient fee
Private provider fees
Chard, S. [47] Uganda 141 47 154
c Private clinic treatment costs
Harper, et al. [53] The Gambia 44 11 54
d Costs spent on private treatment
Needham, et al. [58] Zambia 24 6 35 Mean costs to see a private physician
(median I$15)
Wyss, et al. [68] Tanzania 38 12 29
e Unit cost for private services
a Income share based on 1996 estimates instead of 1995;
b Income share based on 1994 estimates instead of 1993;
c Income share based on 1999 estimates
instead of 1998;
d Income share based on 1998 estimates instead of 2000;
e Income share based on 2000 estimates instead of 1996.
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Author(s) (year) Country Cost
estimate (I$)
% Annual per-
capita income
(entire population)
% Annual per-
capita income
(income-poorest 20%
of the population)
Notes
Hospitalization costs
Aspler, et al. [41] Zambia 14 3 16 Median costs (IQR I$4- I$19)
Floyd, et al. [51] South Africa 119 3 17
a Mean cost of 18-day hospital stay
under DOTS (I$7 per day)
Floyd, et al. [51] South Africa 407 11 59
a Mean cost of 60-day hospital stay
under conventional system (I$7/day)
Floyd, et al. [50] Malawi 498 262 1048 Mean cost of 58-day hospital stay
under hospital-based strategy for
smear-positive patients (I$9/day)
Floyd, et al. [50] Malawi 138 73 289 Mean cost of 16-day hospital stay
under community-based DOTS strategy
for smear-positive patients (I$9/day)
Floyd, et al. [50] Malawi 32 17 66 Mean cost of 8-day hospital stay under
hospital-based and community-based
DOTS strategies for smear-negative
patients (I$9/day)
Gibson and Boillot [52] Sierra Leone 1 0.53 2
b Mean hospital admission fees at a
missionary hospital
Gibson and Boillot [52] Sierra Leone 47 18 58
b Mean hospital admission fees at a
government hospital
Mesfin, et al. [55] Ethiopia 4 2 5 Mean cost of hospital admissions
(median I$0)
Nganda, et al. [60] Kenya 530 101 336
c Mean cost of 60-day hospital stay
under hospital-based system for smear-
positive patients (I$9/ day) (96% CI I$5- I$13)
Nganda, et al. [60] Kenya 34 7 22
c Mean cost of 4-day hospital stay under
community-based DOTS for smear-
positive patients (I$9/ day) (96% CI I$5- I$13)
Okello, et al. [61] Uganda 219 73 240
d Mean cost of 60-day hospital stay under
conventional hospital-based care strategy
for smear-positive patients (I$4/ day)
Okello, et al. [61] Uganda 70 24 77
d Mean cost of 19-day hospital stay under
community-based care strategy for smear-
positive patients (I$4/ day)
Saunderson, P. [31] Uganda 91 39 126 Mean cost for a 2-month hospital stay
Wilkinson, et al. [67] South Africa 139 3.62 20
e Mean cost of 17.5-day hospital stay under
community-based DOTS strategy (I$8/ day)
Wyss et al. [68] Tanzania 15 5 12
f Hospitalization costs reported for one
month
Medication costs
Aspler, et al. [41] Zambia 15 3 18 Median costs for additional medications
(IQR I$9- I$21)
Awofeso, N. [42] Nigeria 548
g 121 589
h Mid-range, one-time medication costs
(range I$199- I$897)
g
Chard, S. [46] Uganda 20 7 22
i Mean costs for medications (range I$4- I$37)
Kemp, et al. [54] Malawi 50 27 106
j Mean costs for smear-negative patients for
user fees and drug costs outside of
government health facilities (median I$19)
Kemp, et al. [54] Malawi 18 9 37
j Mean costs for smear-positive patients for
user fees and drug costs outside of
government health facilities (median I$6)
Mesfin, et al. [55] Ethiopia 22 12 25 Mean costs for additional medications
(median I$7)
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indirect patient costs for TB patients and their house-
holds can be substantial and often “catastrophic” for
average income earners and, in particular, for those in
the income-poorest 20% of the population—the pro-
portion of the population most at-risk of acquiring TB.
The data we extracted from the literature thus suggest
that expenditures for TB treatment and care can cause
or exacerbate poverty. TB patients in sub-Saharan
Africa incur both substantial direct and indirect costs
before, during, and after a TB diagnosis. The largest
costs these patients incur are for hospitalization, medi-
cation, transportation, and treatment or care in the
private sector. In addition, caregivers incur substantial
indirect, or time costs, of providing care or support
for TB patients.
Results also show that total TB treatment and care
costs vary greatly between studies: from only I$2 in
Table 4 Hospitalization, medication, and diagnostic test costs (Continued)
Diagnostic test costs
Aspler, et al. [41] Zambia 7 2 8 Median cost for chest radiographic
(IQR I$4-I$7)
Needham, et al. [58] Zambia 9 2 13 Mean cost for diagnostic tests (unspecified)
(median I$13)
Wyss, et al. [68] Tanzania 10 3 7
f Unit cost for examination, laboratory, and
X-rays
a Income share based on 1995 estimates instead of 1994;
b Income share assumed to be 6% by authors in absence of World Bank data;
c Income share based on
1997 estimates instead of 1998;
d Income share based on 1999 estimates instead of 1998;
e Income share based on 1995 estimates instead of 1996;
f Income
share based on 2000 estimates instead of 1996;
g Note: the study listed these costs as “prepayment fees,” but the costs were actually for medications. Moreover,
these medication costs are reported with imprecision (i.e., a wide range), weakening the strength of the conclusion that TB medication costs were high in Nigeria;
h Income share based on 1992 estimates instead of 1993;
i Income share based on 1999 estimates instead of 1998;
j Income share based on 1998 estimates
instead of 2000.
Table 5 Traditional healer and food costs
Author(s) (year) Country Cost
estimate (I$)
% Annual per-
capita income
(entire population)
% Annual per-
capita income
(income-poorest 20%
of the population)
Notes
Traditional healer costs
Brouwer, et al. [44] Malawi 4 2 9
a Weighted mean of traditional healer
costs (range I$0- I$28)
b
Chard, S. [47] Uganda 563 188 618
c One study participant reported this
cost for a traditional healer
Chard, S. [46] Uganda 15 5 16
c Mid-point estimate (range I$2-I$10).
A few patients in the sample reported
to pay roughly I$495
Needham, et al. [58] Zambia 17 4 25 Average cost to see a traditional
healer (median I$7)
Wyss, et al. [68] Tanzania 13 4 10
d Unit cost to see a traditional healer
Food costs
Aspler, et al. [[41] Zambia 4 0.78 4 Median food costs (IQR I$1- I$7)
Datiko and Lindtjørn [48] Ethiopia 14 7 15
e Mean food costs for a community-based
DOTS treatment program (sd I$12)
Datiko and Lindtjørn [48] Ethiopia 36 17 37
e Mean food costs for a health-facility-
based DOTS treatment program (sd I$21)
Kemp, et al. [54] Malawi 7 4 15
f Mean food costs for smear-negative
patients (median I$2)
Kemp, et al. [54] Malawi 10 5 21
f Mean food costs for smear-positive
patients (median I$0)
Needham, et al. [58] Zambia 3 1 5 Mean food cost (median I$2)
Needham, et al. [58] Zambia 36 9 53 Mean cost for “special” foods
g
(median I$19)
a Income share based on 1998 estimates instead of 1995;
b43% of patients in the sample who sought care from traditional healers paid no charge, 21% paid
under I$0.92, 24% paid between I$0.92 and I$5, 6% paid between I$6 and I$14, and the remaining 6% paid between I$14 and I$28;
c Income share based on 1999
estimates instead of 1998;
d Income share based on 2000 estimates instead of 1996;
e Income share based on 2005 estimates instead of 2006;
f Income share
based on 1998 estimates instead of 2000;
g Defined as food separate from normal diets such as potatoes, eggs, meat, fruit, and soft drinks [58].
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Author(s) year Country Cost
estimate (I$)
% monthly per-
capita income
(entire population)
% monthly per-
capital income
(income-poorest 20%
of the population)
Notes
Aspler, et al. [41] Zambia 3 8 43 Median costs for pre-diagnosis (IQR I$1- I$7)
Aspler, et al. [41] Zambia 12 31 171 Median costs for pill collection visits
(IQR I$4- I$29)
Aspler, et al. [41] Zambia 4 10 57 Median costs for follow-up visits (IQR I$2- I$4)
Bevan, E. [43] Kenya 5 11 35 Daily cost to travel to a designated DOTS
center
Cambanis, et al. [45] Ethiopia 7 47 100
a Mean costs for transport to a health facility
Chard, S. [46] Uganda 3 14 45
b Mean transportation costs to a health
facility in Kampala
Chard, S. [46] Uganda 5 21 67
b Mean transportation costs to a health
facility in Mukono
Datiko and Lindtjorn [48] Ethiopia 2 14 31
c Mean transport costs for a community-
based DOTS treatment program (sd I$5)
Datiko and Lindtjorn [48] Ethiopia 15 88 188
c Mean transport costs for a health facility-
based DOTS treatment program (sd I$43)
Edginton, et al. [49] South Africa 3 0.96 7
d Mid-point costs for 69% of hospital
attendees and 48% of clinic attendees
(range I$0.52-I$5)
e
Floyd, et al. [51] South Africa 12 4 20
f Mean travel cost for a hospital visit
Floyd, et al. [51] South Africa 2 0.74 4
f Mean travel cost for a health clinic visit
Floyd, et al. [51] South Africa 0.17 0.05 0.30
f Mean travel cost for a health clinic DOTS visit
Floyd, et al. [51] South Africa 0.85 0.27 1
f Mean travel cost for a TB ward DOTS visit
Floyd, et al. [50] Malawi 4 26 102 Mean costs for visit to a health center to
collect drugs for smear-positive and
-negative patients under hospital and
community-based strategies (I$18 for
average 5 visits)
Harper, et al. [53] The Gambia 0.55 2 8
g Mean daily fare to attend a TB clinic
(range I$0.44-I$0.66)
Kemp, et al. [54] Malawi 18 116 456
h Mean transport costs for smear-positive
patients (median I$11)
Kemp, et al. [54] Malawi 13 81 319
h Mean transport costs for smear-negative
patients (median I$5)
Mesfin, et al. [55] Ethiopia 11 72 155 Mean transport costs for visiting a public
health facility pre-diagnosis
Needham, et al. [58] Zambia 9 26 150 Mean transportation cost during treatment
(median I$3)
Nganda, et al. [60] Kenya 9 20 67
i Mean cost for a visit to collect drugs from
a health facility for smear-positive patients
under conventional and community-based
strategies for smear-positive patients
(I$44 for average 5 visits)
j
Okello, et al. [61] Uganda 6 24 78
k Mean costs to the nearest health facility in
an outpatient system and costs to collect
drugs under the conventional hospital-based
care strategy and the community-based
care strategy for smear-positive patients (I$37
for average 5 visits)
Sinanovic, et al. [63] South Africa 0.40 0.13 0.69
m Mean cost for monitoring and collection of
drugs and a clinic-based DOTS visit in
Guguletu, Cape Town (95% CI I$0.20- I$0.60)
Sinanovic, et al. [63] South Africa 0.30 0.09 0.52
m Mean cost for monitoring and collection of
drugs and a clinic-based DOTS visit in Nyanga,
Cape Town (95% CI I$0.10- I$0.50)
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estimated costs. Additionally, the types of costs that
patients often pay are numerous: eleven main categories
of costs were captured in this review, and nine of the
thirty studies reported costs in at least five of these cost
categories. Though patients in sub-Saharan Africa often
do not incur all of these fees, merely paying for one
or some of them can have substantial impacts on their
economic circumstances.
Patient costs may negatively impact health-seeking
behaviors, leading to delays in hospital presentation, fur-
ther worsening of disease and increasing risk of disease
spread [16]. Patients adopt several mechanisms to cope
with these costs ranging from asset selling, borrowing,
and diversifying income-generating activities [19,20]. In
order to alleviate the financial burden borne by TB
patients, policy makers should consider incorporating
policies to support patients receiving TB treatment into
general financing and risk-pooling strategies, such as
tax-based or social insurance systems as used by many
developed and, increasingly, developing economies.
While in some settings strategies aimed at reducing
patient costs incurred when utilizing healthcare may
be feared to lead to increases in demand for health-
care exceeding the underlying need, in many develop-
ing countries like those in sub-Saharan Africa,
healthcare demand is currently far below need, in-
cluding for the priority diseases TB and HIV, so that
financial and non-financial support for healthcare
seeking is likely to contribute substantially to improv-
ing population health [70,71]. In addition to the dir-
ect benefits to the treated patient, TB treatment also
reduces onward transmission of the disease in the
community. This positive externality needs to be
taken into account when considering public invest-
ments to decrease the costs patients bare when utiliz-
ing TB care.
Comparable types and extents of costs incurred by
patients in sub-Saharan have been found in studies asses-
sing the household financial burden of other infectious
diseases including malaria and HIV/AIDS. Although some
health districts in sub-Saharan Africa provide free care for
HIV/AIDS and malaria patients, studies assessing the bur-
den of expenditures for malaria and HIV/AIDS-affected
households have found that costs are commonly “cata-
strophic,” a general finding that conforms with our results
for the case of TB. Moreover, the main types of costs that
patients and households incurred based on these studies
were similar to those found in our review: direct costs of
transportation for patients and caregivers, medications,
diagnostic tests, hospitalization, food, medical consulta-
tions, and traditional healers, as well as the indirect costs
such as loss of time at work or school [34,72-76].
More research needs to be done in order to assess the
burden of costs to TB patients in other geographical
areas, including in the 36 other countries in sub-Saharan
Africa for which our systematic review could not identify
any empirical estimates of TB treatment and care costs.
While our results broadly support calls for health policy
changes to alleviate patients’ financial burdens of TB
treatment, it is unclear which particular interventions
will be most effective and cost-effective. Examples of
interventions that can reduce the direct patient expendi-
tures for TB treatment include free transport between
communities and TB treatment facilities, food vouchers
given to TB patients when visiting a facility, and system-
atic elimination of user fees. Interventions that can
reduce indirect patient expenditures for TB treatment
include improved health infrastructure, such as, add-
itional TB treatment facilities, better transport infra-
structure (to decrease the time spent travelling from a
household to a healthcare facility), as well as improved
patient scheduling systems (to decrease patient wait
times at healthcare facilities).
Table 6 Travel costs (Continued)
Vassall, et al. [65] Ethiopia 70 444 952 Mean pretreatment transportation costs
(median I$4)
n
Wilkinson, et al. [67] South Africa 5 2 9
o Average cost of a visit to a village clinic
p
Wilkinson, et al. [67] South Africa 20 6 34
o Average cost of a visit to a hospital
p
Wilkinson, et al. [67] South Africa 1 0.43 2
o Average cost of a village clinic DOTS visit,
a community health worker DOTS visit, and
a non-health worker DOTS visit
p
Wyss, et al. [68] Tanzania 9 32 83
q Weekly transportation costs
a Income share based on 2005 estimates instead of 2004;
b Income share based on 1999 estimates instead of 1998;
c Income share based on 2005 estimates
instead of 2006;
d Income share based on 1993 estimates instead of 1994;
e 29% of hospital attendees and 52% of clinic attendees reported to pay no cost in
transportation fees, and 2% of hospital attendees and 0 clinic attendees paid more than I$5;
f Income share based on 1995 estimates instead of 1996;
g Income
share based on 1998 estimates instead of 2000;
h Income share based on 1998 estimates instead of 2000;
i Income share based on 1997 estimates instead of
1998;
j The conventional was approach used until 1997 in which new patients were hospitalized for the first month of treatment and subsequently provided
unsupervised treatment for the next 11 months. The community-based approach was used after 1997 in which patients spent the first 2 months of treatmenti n
DOTS outpatient programs and the remaining 6 months of treatment in unsupervised outpatient visits;
k Income share based on 1999 estimates instead of 1998;
l Income share based on 2004 estimates instead of 2005;
m Income share based on 1995 estimates instead of 1997;
n Note: these costs are over several months—
the authors did not report single transportation costs;
o Income share based on 1995 estimates instead of 1996;
p Note: these costs include indirect time costs;
q Income share based on 2000 estimates instead of 1996.
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Author(s) year Country Cost
estimate (I$)
% Annual per-
capita income
(entire population)
% Annual per-
capita income
(income-poorest 20%
of the population)
Notes
Direct costs
Aspler, et al. [41] Zambia 11 2 13 Total direct costs including medical
and non-medical costs (IQR I$6- I$17)
Datiko and Lindtjorn [48] Ethiopia 17 8 17 Direct patient costs under
community-based DOTS (sd I$12)
Datiko and Lindtjorn [48] Ethiopia 49 24 51 Direct patient costs under health
facility-based DOTS (sd I$44)
Kemp, et al. [54] Malawi 39 21 83
a Mean total direct costs for smear-
positive patients (median I$19)
Kemp, et al. [54] Malawi 74 40 156
a Mean total direct costs for smear-
negative patients (median I$38)
Mesfin, et al. [55] Ethiopia 114 60 129 Mean total direct costs
(median I$61; IQR I$26- I$132)
Needham, et al. [57] Zambia 64 16 73 Total mean direct costs
Needham, et al. [58] Zambia 14 3 20 Total mean direct medical costs
(median I$5)
Needham, et al. [58] Zambia 31 8 45 Total mean direct non-medical
costs (median I$14)
Vassall, et al. [65] Ethiopia 527 277 595 Total mean direct pretreatment
costs including transport and non-
transport costs for (median I$66)
Wandwalo, et al. [66] Tanzania 59 17 33
b Total direct costs under a health
facility-based DOTS strategy
Wandwalo, et al. [66] Tanzania 13 4 8
b Total direct costs under a
community-based DOTS strategy
Indirect Costs
Aspler, et al. [41] Zambia 21 5 25 Median total indirect costs
(IQR I$11- I$39)
Datiko and Lindtjorn [48] Ethiopia 18 9 18 Mean indirect cost under
community-based DOTS
Datiko and Lindtjorn [48] Ethiopia 48 50 24 Mean indirect cost under health
facility-based DOTS
Mesfin, et al. [55] Ethiopia 145 76 164 Average indirect costs from first
consultation to diagnosis including
income lost and travel time cost
(median I$44; IQR I$15- I$101)
Mesfin, et al. [55] Ethiopia 54 28 60 Average indirect costs prior to
diagnosis (median I$26.) including
income last and travel time cost
Needham, et al. [58] Zambia 99 25 145 Total lost income (median I$37)
Vassall, et al. [65] Ethiopia 44 23 50 Total mean indirect pretreatment
costs (median I$0)
Wandwalo, et al. [66] Tanzania 56 16 32
b Total indirect costs under a health
facility-based DOTS strategy
Wandwalo, et al. [66] Tanzania 19 5 11
b Total indirect costs under a
community-based DOTS strategy
Total Costs
Aspler, et al. [41] Zambia 34 7 41 Total median costs per patients (IQR
I$19-I$56) in which direct and
indirect costs comprised 34% and
62%, respecitvely
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Chard, S. [46] Uganda 25 8 27
c Total reported costs for biomedical
treatment
Datiko and Lindtjorn [48] Ethiopia 34 17 36
d Total patient costs under
community-based DOTS (sd I$16)
Datiko and Lindtjorn [48] Ethiopia 99 48 104
d Total patient costs under health
facility-based DOTS (sd I$50)
Floyd, et al. [51] South Africa 155 4 23
e Total cost to patients under DOTS
Floyd, et al. [51] South Africa 461 12 67
e Total cost to patients under the
conventional system
f
Gibson and Boillot [52] Sierra Leone 26 10 33
g Total cost for patients under the
National Leprosy and TB Control
Program
Mesfin, et al. [55] Ethiopia 259 136 292 Mean total costs (median I$119;
IQR I$53- I$242)
Needham, et al. [58] Zambia 68 17 100 Total patient costs (median I$32)
Saunderson, P.R. [31] Uganda 584 249 809 Total cost under the strategy that
utilizes hospitalization for the first
two months of treatment followed
by an outpatient continuation phase
for 4–10 months.
Sinanovic and Kumaranayake [64] South Africa 102 3 17
h Total cost per patient attending a
public-non-governmental
organization partnership site
(95% CI I$73- I$123)
Sinanovic and Kumaranayake [64] South Africa 95 2 16
h Total cost per patient attending a
public-non-governmental
organization partnership site
(95% CI I$82- 104)
Sinanovic and Kumaranayake [64] South Africa 264 7 44
h Total cost per patient attending a
public hospital (95% CI I$251- I$274)
Sinanovic and Kumaranayake [64] South Africa 317 8 53
h Total cost per patient attending a
public hospital (95% CI I$293- I$363)
Sinanovic, et al. [63] South Africa 2 0.044 0.24
i Total cost for a clinic DOTS visit, where
clinic used for DOTS and total cost
for monitoring/collection of drugs
in Nyanga (95% CI I$1- I$2)
Sinanovic, et al. [63] South Africa 2 0.041 0.23
i Total cost for a clinic DOTS visit, where
clinic used for DOTS and total cost
for monitoring/collection of drugs
in Guguletu (95% CI I$1- I$2)
Sinanovic, et al. [63] South Africa 1 0.01 0.08
i Total cost for a DOTS visit, where
community treatment supporter u
used for in Guguletu (95% CI I$1- I$2)
Vassall, et al. [65] Ethiopia 567 298 639 Total mean pretreatment costs
Wandwalo, et al. [66] Tanzania 116 32 65
b Total costs under a health facility-
based DOTS strategy
Wandwalo, et al. [66] Tanzania 32 9 18
b Total costs under a community-
based DOTS strategy
Wilkinson, et al. [67] South Africa 183 5 27
j Total costs for patients treated under
community-based DOTS strategy.
a Income share based on 1998 estimates instead of 2000;
b Income share based on 2000 estimates instead of 2005;
c Income share based on 1999 estimates
instead of 1998;
d Income share based on 2005 estimates instead of 2006;
e Income share based on 1995 estimates instead of 1996;
f The conventional system
hospitalizes patients for the first two months of treatment;
g Income share assumed to be 6% by authors in absence of World Bank data;
h Income share based on
2000 estimates instead of 2001;
i Income share based on 1995 estimates instead of 1997;
j Income share based on 1995 estimates instead of 1996;
k Income share
based on 2000 estimates instead of 1996.
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Author(s) (year) Country Catastrophic Costs for Average
Income Earners
Range (% of
annual income)
Catastrophic Costs for Lowest 20% Range (% of
annual income)
Aspler, et al. (1998) [41] Zambia Total 12 Total, direct, indirect, pre-diagnosis, treatment,
time, transportation, medication, hospitalization,
direct clinic-based DOTS, indirect clinic-based
DOTS
12-40
Awofeso, N. (1998) [42] Nigeria Medication 121 Medication 589
Bevan, E. (1997) [43] Kenya ___ ___ Medication, syringes and needles 11-32
Chard, S. (2001) [46] Uganda Medication, traditional healer,
“tipping” providers
12-165 Medication, traditional healer, “tipping” providers 41-544
Chard, S. (2009) [47] Uganda Private provider, traditional healer 47-188 Private provider, traditional healer 154-618
Datiko and Lindtjørn (2010) [48] Ethiopia Total, travel, time, caregiver, direct, food 17-48 Total, travel, time, caregiver, direct, food 15-104
Floyd, et al. (2003) [50] Malawi Travel, hospitalization, DOTS visit 13-262 Travel, hospitalization 18-1043
Floyd, et al. (1997) [51] South Africa Total, hospitalization 11-12 Total, hospitalization 17-67
Gibson, et al. (1998) [52] Sierra Leone pre-program, program, hospital
admission fees
17-88 Total, pre-program, program, hospital
admission fees
32-287
Harper, et al. (2003) [53] The Gambia Private treatment 11 Private treatment 54
Kemp, et al. (2007) [54] Malawi Direct, income lost, user fees and
medication, pre-diagnosis
21-40 Direct, income lost, user fees and medication,
pre-diagnosis, food, travel
15-155
Mesfin, et al. (2010) [55] Ethiopia Medical, non-medical, indirect, direct,
medication, caregiver, total
11-136 Medical, non-medical, indirect, direct,
medication, caregiver, travel, total
12-292
Moalosi, et al. (2003) [56] Botswana Total caregiver costs Caregiver
hospitalization Caregiver food and supplies
13-51 Total caregiver costs, caregiver
hospitalization, caregiver medication,
caregiver food and supplies
29-258
Needham, et al. (1996) [57] Zambia Total medical, direct, income lost 16-148 Total medical, total non-medical, direct,
income lost
43-688
Needham, et al. (1998) [58] Zambia Total, indirect, pre-diagnosis, non-medical,
food
11-47 Total, indirect, pre-diagnosis, non-medical,
medical, food, diagnostic tests, caregiver,
private provider, traditional healer, consultation
fees, travel,
15-214
Needham, et al. (2004) [59] Zambia ___ ___ Transportation 11
Nganda, et al. (2003) [60] Kenya Hospitalization, travel 33-101 Hospitalization, travel 22-336
Okello, et al. (2003) [61] Uganda Hospitalization, travel 12-73 Hospitalization, travel 40-241
Saunderson, P.R. (1995) [31] Uganda Total, hospitalization, pre-diagnosis, indirect 34-249 Total, hospitalization, pre-diagnosis, indirect 111-809
Sinanovic, et al. (2003) [63] South Africa ___ ___ Total 11-43
Sinanovic and Kumaranay-ake (2006) [64] South Africa ___ ___ Total, time, travel 11-53
Vassall, et al. (2010) [65] Ethiopia Direct, indirect, travel and total pretreatment 23-298 Direct, indirect, travel and total
pretreatment
50-639
Wandwalo, et al. (2005) [66] Tanzania Total, direct, indirect 16-32 Total, direct, indirect 18-65
Wilkinson, et al. (1997) [67] South Africa ___ ___ Total, hospitalization 20-27
Wyss, et al. (2001) [68] Tanzania Private provider 12 Traditional healer, private provider, hospitalization 10-29
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0Finally, since we find that patients in some countries
spend substantial amounts of money for TB treatment
and care in the private sector despite public-sector TB
programs that offer some services free of charge, inter-
ventions to decrease the demand for private-sector TB
treatment and care could reduce the financial burden to
TB patients. Such interventions could improve media
campaigns to ensure that patients are aware of where
and when they can access public-sector TB treatment
and health sector reforms leading to increased quality of
care in the public sector. Rigorous evaluation studies, ac-
companying the implementation of such interventions,
will contribute to our understanding of their perform-
ance and impact on patient healthcare expenditures and
population health outcomes.
Limitations
There are several limitations of this review: First, we
included studies that were conducted from 1994 to
present. Earlier studies might not be generalizable to
current strategies because TB control program policies
may have changed since their publication. Second,
although no official criteria exist for assessing studies on
patient costs, other systematic reviews of patient costs
have used various quality assessment criteria for evaluat-
ing study quality [23,77-79]. Due to our broader study
inclusion criteria, we were unable to adopt similar
formal criteria for evaluating study quality beyond ensur-
ing that studies had clearly defined objectives, clearly
defined study populations, and a quantitative measure of
patient-costs. This limitation may have led to a relatively
higher weight placed on results from “low quality” stud-
ies in the interpretation and discussion of the summary
findings from our systematic review than would have
been the case if we could have more clearly distin-
guished between “low” and “high quality” studies.
Third, many studies assessed only a few specific types
of costs, so comparing total cost burden to patients
across studies is difficult and may be underestimated.
Similarly, the studies that reported aggregate direct and
indirect costs might have defined direct and indirect
costs differently, so these reported measures might not
be comparable. Additionally, since costs were measured
differently and may reflect different time periods, (for
instance some travel costs were measured as one-time
costs, and others were measured over the entire course
of treatment), comparing these cost burdens on patients’
average annual or monthly income are difficult and must
be interpreted with caution.
Moreover, only five studies directly surveyed patients
on their incomes. In our estimation of the impact of TB
patient costs on patients’ economic circumstances, we
thus had to rely on national income estimates. However,
it is very likely that TB patients’ average income deviates
substantially from the national average, so that our rela-
tive measures of the out-of-pocket cost burden to
patients and households may be biased.
Furthermore, since data on income shares of the
income-poorest 20% of the population were missing for
several country-years, we used estimates from the closest
years for which data were available for a country, but
this could potentially yield inaccurate estimates of per
capita GDP for this portion of the population. Finally,
evidence on TB patient costs was only available for 11
out of 47 countries in sub-Saharan Africa. Results from
these studies cannot be extrapolated to the rest of the
continent, and it is possible that patients in other parts
of Africa might incur lower TB patient costs.
Conclusion
Tuberculosis can place considerable financial and eco-
nomic burden on patients and households in sub-Saharan
Africa. Here, we identified 30 relevant studies investigating
TB patient costs in sub-Saharan Africa before, during and
after diagnosis and treatment for TB. We found that pa-
tient costs vary considerably both by total amounts and
according to the different types of costs incurred by
patients in DOTS and non-DOTS settings. In many set-
tings, patient costs were found to be “catastrophic” in that
they amounted to 10% or more of average annual
incomes. These costs have the potential to financially
strain patients and their households, leading to detrimen-
tal effects such as delayed care seeking and increased de-
fault rates of TB patients, potentially fueling the spread of
TB or increasing multi-drug resistant TB in sub-Saharan
Africa. Future research needs to assess which interven-
tions and health systems reforms are most effective and
cost-effective in reducing the financial burdens that
patients incur when seeking TB treatment and care.
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